A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-07-02
Adverse events
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 25); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 25); relationship: N; serious criteria: hospitalization
Grade 2 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 28); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-08-16 (study day 30); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-27 (study day 41); relationship: N
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-29 (study day 43); relationship: N
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-09-21 (study day 66); relationship: not assessed
Data queries
No data queries.